14 days of Premium, free.
Every scanner with live hit rates + the Market Pulse risk flag that tells you when to get defensive. No card required.
Start trial →
Tradestie Institutional Equity Comparison Engine · Market Close Nov 17, 2026
ANNX vs CCCC: Which Stock Is the Better Buy Now?
Deterministic 6-pillar institutional evaluation across valuation multiples, TTM & multi-year operating margins, cash generation, options IV skew, and supply-chain moat.
As of Nov 17, 2026, Annexon, Inc. (ANNX) is the stronger overall head-to-head candidate over C4 Therapeutics, Inc. (CCCC) in the Tradestie Institutional Equity Comparison Engine, winning 5–3 core matrix metrics and 4–1 across our 6-pillar institutional scorecard (led by Growth & Scale, Profitability & Quality, Balance Sheet & Cash Flow). ANNX carries a Unified Composite Score of 43.5/100 (HOLD) at $3.48 (N/M Forward P/E, 0.0% operating margin), whereas CCCC carries 47.7/100 (HOLD) at $2.50 (N/M Forward P/E, -315.9% operating margin).
Composite vs. Pillar Nuance: While CCCC currently prints a higher short-term Unified Composite Score (47.7/100 HOLD vs. ANNX 43.5/100 HOLD), ANNX captures the overall institutional head-to-head verdict (5–3 matrix metrics and 4–1 across the 6 pillars) due to superior fundamental profitability (0.0% vs. -315.9% operating margin) and revenue trajectory (+0.0% vs. -24.6% YoY).
Technical & Structure Timing Caution: ANNX is currently in a short-term Weinstein Markdown pullback below its falling 50-day moving average and Breakdown options structure phase (RSI 36.3); meanwhile CCCC is in a short-term Weinstein Markdown pullback below its falling 50-day moving average and Breakdown options structure phase (RSI 34.2). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.
Standardized multi-year USD domestic revenue schedules are unavailable for foreign-domiciled ADR filing schedules on ANNX vs CCCC. Trailing 12-month operating profitability (ANNX 0.0% vs CCCC -315.9%) and valuation multiples (ANNX N/M vs CCCC N/M Forward P/E) are benchmarked directly in Pillar 4 below.
Competes within the Biotechnology value chain with $362.4M market capitalization and -315.9% operating margin.
OpEx & R&D ReinvestmentN/A
90D Engineering Disclosures0 Published
Investor FAQ ANNX vs CCCC Key Questions & Quantitative Answers
As of Nov 17, 2026, Annexon, Inc. (ANNX) is the stronger overall head-to-head candidate over C4 Therapeutics, Inc. (CCCC) in the Tradestie Institutional Equity Comparison Engine, winning 5–3 core matrix metrics and 4–1 across our 6-pillar institutional scorecard (led by Growth & Scale, Profitability & Quality, Balance Sheet & Cash Flow). ANNX carries a Unified Composite Score of 43.5/100 (HOLD) at $3.48 (N/M Forward P/E, 0.0% operating margin), whereas CCCC carries 47.7/100 (HOLD) at $2.50 (N/M Forward P/E, -315.9% operating margin). Composite vs. Pillar Nuance: While CCCC currently prints a higher short-term Unified Composite Score (47.7/100 HOLD vs. ANNX 43.5/100 HOLD), ANNX captures the overall institutional head-to-head verdict (5–3 matrix metrics and 4–1 across the 6 pillars) due to superior fundamental profitability (0.0% vs. -315.9% operating margin) and revenue trajectory (+0.0% vs. -24.6% YoY). Technical & Structure Timing Caution: ANNX is currently in a short-term Weinstein Markdown pullback below its falling 50-day moving average and Breakdown options structure phase (RSI 36.3); meanwhile CCCC is in a short-term Weinstein Markdown pullback below its falling 50-day moving average and Breakdown options structure phase (RSI 34.2). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.
ANNX leads the Growth & Scale pillar: ANNX posts +0.0% YoY revenue growth and +0.0% YoY earnings growth on N/A TTM revenue (N/A gross margin, 0.0% operating margin), compared with CCCC at -24.6% YoY revenue growth and +0.0% YoY earnings growth on $32M TTM revenue (88.8% gross margin, -315.9% operating margin). On trailing 12-month operating scale, ANNX generates N/A in USD-normalized revenue versus $32M for CCCC. In operating R&D and SG&A reinvestment, ANNX deploys N/A (0 90-day corporate R&D disclosures) versus N/A (0 disclosures) for CCCC.
CCCC screens cheaper on headline valuation multiples. ANNX trades at N/M Forward P/E, N/M Trailing P/E, N/M PEG, and N/M EV/Revenue (unreported FCF margin), whereas CCCC trades at N/M Forward P/E, N/M Trailing P/E, N/M PEG, and 11.9x EV/Revenue (unreported FCF margin). Multiples above 150x or negative earnings denominators are marked N/M to avoid distorted accounting comparisons; weigh lower Forward P/E and PEG against ANNX (-130.8% ROE) versus CCCC (-47.6% ROE) capital efficiency.
In options market volatility and institutional positioning, ANNX carries 569.3% implied volatility (100th %ile, Extreme (>80th %ile)), a 0.09x (Call-Skewed) Put/Call open-interest ratio, DISTRIBUTION on-balance volume, and sits in a BREAKDOWN options structure phase (1.69β · 63% Vol realized risk). By comparison, CCCC carries 79.8% implied volatility (3rd %ile, Compressed (<25th %ile)), a 0.41x (Call-Skewed) Put/Call open-interest ratio, DISTRIBUTION on-balance volume, and sits in a BREAKDOWN options structure phase (1.46β · 68% Vol realized risk).
Cross-Compare 1-Click Peer Rivalries & Single-Stock Research
Powered by Tradestie Institutional Equity Comparison Engine & standardized corporate financial telemetry. Market close as of Nov 17, 2026. For educational research only; not investment advice.